Figure 2: Increase expression of HES1 in cisplatin based chemotherapeautic HNSCC.

(A) Representative hematoxylin-eosin and immunohistochemical staining of HES1in HNSCC patient receiving TPF neoadjuvant chemotherapy with quantitative histoscore in (B) Scale bar, 50 μm. (C) Representative immunohistochemical staining of HES1 with quantitative histoscore Representative hematoxylin-eosin and immunohistochemical staining of HES1in HNSCC patient receiving TPF neoadjuvant chemotherapy with quantitative histoscore in (D). Each sample score present as a dot, paired t test, *P < 0.05; ***P < 0.001.